leadf
logo-loader
viewVolitionRx

VolitionRx welcomes proof of concept results as its Nu.Q assay detects two cancers common in dogs

At a specificity of 90%, a single Nu.Q Vet assay detected almost 70% of both Canine Hemangiosarcoma and Canine Lymphoma, the firm revealed

VolitionRx -
The study was completed at the Texas A&M University (TAMU)

VolitionRx Limited (NYSEAMERICAN:VNRX), the cancer diagnostics group, has moved a step closer to launching its first Nu.Q Vet product in the US as it unveiled positive results from its first proof of concept study.

The study was completed at the Texas A&M University (TAMU) and showed the test detected two cancers common in dogs.

READ: VolitionRx actively developing coronavirus (COVID-19) triage test using its proprietary Nu.QTM platform

At a specificity of 90%, a single Nu.Q Vet assay detected almost 70% of both Canine Hemangiosarcoma and Canine Lymphoma, the firm revealed. These two diseases represent a  third of all canine cancers.

"It is exciting to see such strong results from our first Nu.Q™ Vet study conducted at Texas A&M University Veterinary Hospital," Dr Terry Kelly,  the chief scientific officer of Volition America said in a statement.

"It is also interesting to note the similar patterns of detection seen in both canine and human samples confirming that the Nu.Q platform does appear to be useful in more than just human diagnostics.

"As with human diagnostics, there are currently no accurate, simple, affordable cancer screening tests available in veterinary medicine and yet 25% of dogs will develop cancer at some stage of their life. I look forward to completing the planned trials and to launch our first Nu.Q Vet product in the U.S. that we expect to occur in 2020."

Dr Heather Wilson-Robles, associate professor at TAMU and chief medical officer of Volition Veterinary Diagnostics, noted that the results had provided the firm with "confidence to move forward with other Vet assays" in the firm's pipeline, and with the larger range of cohorts and trials.

"Clearly, we still have work to do as this single assay did not detect one of the other top five canine cancers, Canine Osteosarcoma, which was the third cancer tested in this study. However, I am delighted to see such positive results in these two significant cancers and look forward to reporting further data over the coming quarters with additional Nu.Q™ Vet assays, this time tested on an automated platform," she said.

Volition's tests are based on the science of Nucleosomics, namely, the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

Volition shares in New York nudged up 0.72% to $4.20.

Contact the author at [email protected]

Quick facts: VolitionRx

Price: 3.38 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $162.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

VolitionRx Limited ends its 3Q with $21M in the bank, looks forward to...

VolitionRx Limited (NYSE AMERICAN:VNRX) CEO Cameron Reynolds tells Proactive the group finished its third quarter with around $21M in the bank compared with $17M at the end of 2019. Reynolds also discussed upcoming milestones including the preparing to launch its new product, Nu.Q™ Vet Cancer...

2 weeks, 1 day ago

2 min read